Drug Profile

MDX 124

Alternative Names: MDX-124

Latest Information Update: 28 Jan 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Medannex
Class Antineoplastics; Immunotherapies; Monoclonal antibodies
Mechanism of Action Annexin A1 inhibitors; Antibody-dependent cell cytotoxicity

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

28 Jan 2025 No recent reports of development identified for phase-I development in Solid-tumours in United Kingdom (IV, Infusion)
25 Oct 2022 Medannex plans a phase I trial for Cancer in UK(ISRCTN78740398)
21 Sep 2022 Phase-I clinical trials in Solid tumours (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in United Kingdom (IV) (ISRCTN-78740398)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com